000294315 001__ 294315
000294315 005__ 20241103013537.0
000294315 0247_ $$2doi$$a10.1038/s41541-024-00949-2
000294315 0247_ $$2pmid$$apmid:39256440
000294315 0247_ $$2pmc$$apmc:PMC11387505
000294315 0247_ $$2altmetric$$aaltmetric:167418181
000294315 037__ $$aDKFZ-2024-02148
000294315 041__ $$aEnglish
000294315 082__ $$a610
000294315 1001_ $$aKemp, Troy J$$b0
000294315 245__ $$aWHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.
000294315 260__ $$a[London]$$bNature Publishing Group$$c2024
000294315 3367_ $$2DRIVER$$aarticle
000294315 3367_ $$2DataCite$$aOutput Types/Journal article
000294315 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730124704_10605
000294315 3367_ $$2BibTeX$$aARTICLE
000294315 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294315 3367_ $$00$$2EndNote$$aJournal Article
000294315 520__ $$aPreviously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.
000294315 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000294315 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294315 7001_ $$aPanicker, Gitika$$b1
000294315 7001_ $$aEklund, Carina$$b2
000294315 7001_ $$aNie, Jianhui$$b3
000294315 7001_ $$aWang, Youchun$$b4
000294315 7001_ $$00000-0002-6879-6215$$aBeddows, Simon$$b5
000294315 7001_ $$aRigsby, Peter$$b6
000294315 7001_ $$00000-0002-4246-8889$$aHuang, Weijin$$b7
000294315 7001_ $$aDillner, Joakim$$b8
000294315 7001_ $$aUnger, Elizabeth R$$b9
000294315 7001_ $$aPinto, Ligia A$$b10
000294315 7001_ $$00000-0001-6936-8629$$aWilkinson, Dianna E$$b11
000294315 7001_ $$aparticipants, collaborative study$$b12$$eCollaboration Author
000294315 7001_ $$aLicciardi, Paul$$b13$$eContributor
000294315 7001_ $$aToh, Zheng Quan$$b14$$eContributor
000294315 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b15$$eContributor$$udkfz
000294315 7001_ $$aRajanathan, T M Chozhavel$$b16$$eContributor
000294315 7001_ $$aLi, Shaowei$$b17$$eContributor
000294315 7001_ $$aXia, Ningshao$$b18$$eContributor
000294315 7001_ $$aLiu, Ge$$b19$$eContributor
000294315 7001_ $$aZhou, Chenliang$$b20$$eContributor
000294315 7001_ $$aZhou, Lingyun$$b21$$eContributor
000294315 7001_ $$aXu, Nan$$b22$$eContributor
000294315 7001_ $$aPanwar, Kavita$$b23$$eContributor
000294315 7001_ $$aGalloway, Denise$$b24$$eContributor
000294315 7001_ $$aCarter, Jody$$b25$$eContributor
000294315 773__ $$0PERI:(DE-600)2882262-6$$a10.1038/s41541-024-00949-2$$gVol. 9, no. 1, p. 165$$n1$$p165$$tnpj vaccines$$v9$$x2059-0105$$y2024
000294315 909CO $$ooai:inrepo02.dkfz.de:294315$$pVDB
000294315 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000294315 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000294315 9141_ $$y2024
000294315 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ VACCINES : 2022$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:19Z
000294315 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:19Z
000294315 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:19Z
000294315 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:19Z
000294315 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ VACCINES : 2022$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000294315 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000294315 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000294315 980__ $$ajournal
000294315 980__ $$aVDB
000294315 980__ $$aI:(DE-He78)D335-20160331
000294315 980__ $$aUNRESTRICTED